

# KEYTRUDA®

(pembrolizumab)

**May cause some serious side effects which can sometimes become life-threatening and lead to death. These may happen any time during treatment or even after your treatment has ended. You may experience more than one side effect at the same time.**

**Contact your doctor right away if you develop any signs or symptoms including those not listed on this card. Your doctor may give you other medicines in order to prevent more severe complications and reduce your symptoms. Your doctor may withhold the next dose of KEYTRUDA or stop treatment with KEYTRUDA.**

## Lungs

- Shortness of breath
- Chest pain
- Coughing

## Intestines

- Diarrhea or more bowel movements than usual
- Stools that are black, tarry, sticky, or contain blood or mucus
- Severe stomach pain or tenderness
- Nausea or vomiting

## Kidneys

- Changes in the amount or color of your urine

## Liver

- Nausea or vomiting
- Feeling less hungry
- Pain on the right side of stomach
- Yellowing of skin or whites of eyes
- Dark urine
- Bleeding or bruising more easily than normal

## Type 1 diabetes

- Feeling more hungry or thirsty
- Needing to urinate more often
- Weight loss

## Hormone glands

- Rapid heartbeat
- Weight loss or weight gain
- Increased sweating
- Hair loss
- Feeling cold
- Constipation
- Deeper voice
- Muscle aches
- Dizziness or fainting
- Headaches that will not go away or unusual headache

## IMPORTANT

- Do not attempt to diagnose or treat side effects yourself.
- **Take this card with you at all times**, especially when you travel, whenever you go to the emergency room, or when you must see another doctor.
- Be sure to notify any health care professional you see that
- you are being treated with KEYTRUDA and show them this card.

For more information, consult the Package Leaflet for KEYTRUDA containing information for the patient. Available at [www.fass.se](http://www.fass.se) and [www.ema.europa.eu](http://www.ema.europa.eu).

## Important Contact Information

My Name

My Phone

Emergency Contact (Name and Phone)

Name of Doctor

Office Phone

After-hours Phone

## Important Information for Health Care Providers

This patient is being treated with KEYTRUDA (*pembrolizumab*), which can cause immune-related adverse reactions that may appear any time during treatment or even after treatment. Assess patients for signs and symptoms of immune-related adverse reactions. Early diagnosis and appropriate management are essential to minimise any consequences of immune-related adverse reactions.

For suspected immune-related adverse reactions, ensure adequate evaluation to confirm aetiology or exclude other causes. Based on the severity of the adverse reaction, withhold KEYTRUDA and administer corticosteroids.

Specific guidelines for managing immune-related adverse reactions are available in the Summary of Product Characteristics for KEYTRUDA.

Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific immune-related adverse reactions.

Please consult the Summary of Product Characteristics for KEYTRUDA at [www.fass.se](http://www.fass.se) and [www.ema.europa.eu](http://www.ema.europa.eu) or call Medical Information at +46 77 570 04 88 for more information.

This material is a translation of the Swedish Patient Alert Card latest review by the Medical Products Agency: Nov 28, 2019

Copyright © 2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved.

SE-KEY-00068 april 2020

MSD, Box 45192, S-104 30 Stockholm, [msd.se](http://msd.se), 08-578 135 00

